Immune-mediated liver injury induced by PD-1/PD-L1 checkpoint inhibitors is different from idiosyncratic drug-induced liver injury

被引：0
|
作者：
Wang, Yan [1 ]
Meng, Yao [1 ]
Zhang, Mengmeng [1 ]
Guo, Tiantian [1 ]
Chen, Wei [1 ]
Liu, Liwei [2 ]
Zhao, Xinyan [1 ]
机构：
[1] Capital Med Univ, Beijing Friendship Hosp, Liver Res Ctr, Natl Clin Res Ctr Digest Dis,Key Lab Translat Med, Beijing, Peoples R China
[2] Capital Med Univ, Beijing Youan Hosp, Dept Liver Dis 4, Difficult & Complicated Liver Dis & Artificial Li, Beijing, Peoples R China
来源：
JOURNAL OF HEPATOLOGY | 2024年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
SAT-326
引用
收藏
页码：S121 / S121
页数：1
相关论文
共 50 条
  • [31] Prospective role of PD-1/PD-L1 immune checkpoint inhibitors in GI cancer
    AmeliMojarad, Mandana
    AmeliMojarad, Melika
    Cui, Xiaonan
    PATHOLOGY RESEARCH AND PRACTICE, 2023, 244
  • [32] Immune-mediated drug-induced liver injury secondary to Omeprazole: A case report
    Seife Hassen, Sara
    Ata, Fateen
    Bilal, Ammara Bint, I
    Salih Ali, Mohamed
    Petkar, Mahir
    Awad Elzouki, Abdelnaser Y.
    Zahid, Muhammad
    CLINICAL CASE REPORTS, 2020, 8 (12): : 3420 - 3425
  • [33] Immune-mediated Drug-induced Liver Injury Caused by Laninamivir Octanoate Hydrate
    Kawaguchi, Toshihiro
    Arinaga-Hino, Teruko
    Shimizu, Motoki
    Tanikawa, Ken
    Tokushige, Takahiko
    Hirai, Shingo
    Nagamatsu, Hiroaki
    Tateishi, Hideo
    Takata, Akio
    Ide, Tatsuya
    Torimura, Takuji
    INTERNAL MEDICINE, 2019, 58 (17) : 2501 - 2505
  • [34] Emerging Role of PD-1/PD-L1 Inhibitors in Chronic Liver Diseases
    Singh, Vishakha
    Khurana, Amit
    Allawadhi, Prince
    Banothu, Anil Kumar
    Bharani, Kala Kumar
    Weiskirchen, Ralf
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [35] Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells
    Skalniak, Lukasz
    Zak, Krzysztof M.
    Guzik, Katarzyna
    Magiera, Katarzyna
    Musielak, Bogdan
    Pachota, Magdalena
    Szelazek, Bozena
    Kocik, Justyna
    Grudnik, Przemyslaw
    Tomala, Marcin
    Krzanik, Sylwia
    Pyrc, Krzysztof
    Domling, Alexander
    Dubin, Grzegorz
    Holak, Tad A.
    ONCOTARGET, 2017, 8 (42) : 72167 - 72181
  • [36] Using individual-centric model to detect immune-mediated idiosyncratic drug-induced liver injury at preclinical stage
    Cherradi, S.
    Roux, S.
    Duong, H. T.
    TOXICOLOGY LETTERS, 2024, 399 : S110 - S111
  • [37] The diagnosis and management of idiosyncratic drug-induced liver injury
    Hassan, Ammar
    Fontana, Robert J.
    LIVER INTERNATIONAL, 2019, 39 (01) : 31 - 41
  • [38] Idiosyncratic drug-induced liver injury: A clinical update
    Maddur H.
    Chalasani N.
    Current Gastroenterology Reports, 2011, 13 (1) : 65 - 71
  • [39] Risk Factors for Idiosyncratic Drug-Induced Liver Injury
    Chalasani, Naga
    Bjornsson, Einar
    GASTROENTEROLOGY, 2010, 138 (07) : 2246 - 2259
  • [40] Exploiting the predictive power of educated spheroids to detect immune-mediated idiosyncratic drug-induced liver injury: the case of troglitazone
    Roux, Salome
    Cherradi, Sara
    Duong, Hong Tuan
    FRONTIERS IN PHARMACOLOGY, 2024, 15
12345